LifeForce Capital

Michael Galbo is the Managing Partner and Portfolio Manager, with sole authority over investment decisions. Galbo built LifeForce around a concentrated healthcare public-equity strategy and is the named manager on all SEC filings, indicating a flat decision-making structure without an investment committee layer.

LifeForce runs a concentrated, long-biased public-equity strategy focused exclusively on healthcare — spanning biotechnology, life sciences tools, diagnostics, and healthcare technology. The firm targets small- to mid-cap companies where it can take meaningful ownership stakes and engage constructively with management teams around capital allocation, pipeline strategy, and operational execution.

LifeForce is structured as a registered investment adviser managing a pooled investment vehicle, placing it closer to a hedge fund than a family office. The firm files quarterly 13F reports with the SEC, confirming it manages outside capital alongside any internal partner assets, though it has not publicly disclosed its investor base.

LifeForce stays entirely within healthcare, avoiding sectors outside its circle of competence — including energy, financials, consumer goods, and general technology. Within healthcare, the firm historically avoids large-cap pharmaceuticals with entrenched pipelines and payer-facing service companies where pricing power is constrained by government reimbursement.

Galbo pursues constructive engagement rather than hostile activism. The firm takes concentrated positions and uses its stake to discuss capital allocation, pipeline prioritization, and operational milestones with management and boards. It has not waged proxy fights or publicly agitated for C-suite turnover in any disclosed campaign.

LifeForce has not publicly disclosed its limited partner base or capital source. The firm's 13F filings confirm it manages a pooled vehicle, which typically includes institutional allocators, family offices, and high-net-worth individuals, but no specific investors have been named in public filings or press reports.

LifeForce is recognized for its narrow, high-conviction healthcare mandate and its willingness to engage directly with management teams at small- and mid-cap biotech companies. The firm's concentrated portfolio — typically 15 or fewer names — signals a research-intensive process that avoids the diversification norms of larger healthcare sector funds.